Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Managing Hypertension in CVD: How Low Can We Go?
Author(s): Yassir Javaid , Michel Burnier , Mariya Tokmakova , et al Start date: Jun 25, 2025
Join an expert panel of internationally recognised cardiovascular specialists for a CME-accredited* webinar on the latest strategies in hypertension management for patients with cardiovascular disease. Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH) Prof Mariya Tokmakova (Medical University… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
ESC 23: Economic Burden of CVD in the EU
Author(s): Ramón Luengo-Fernández Added: 2 years ago
ESC 2023 — Dr Ramón Luengo-Fernández (University of Oxford, UK) joins us on-site to discuss the findings from a registry which aimed to analyse the economic burden of cardiovascular disease within the EU. This was the first study to utilise Europe-wide patient registries and included the costs of long-term social care. Results from the registry found that cardiovascular disease cost the EU €282… View more

Guidelines & Statements
AHA 24: The LIBerate-OLE Trial
Author(s): Dean J Kereiakes Added: 11 months ago
AHA Conference 2024 - Long-term safety and efficacy outcomes from 48 and 72 weeks of LIB003 (LIB Therapeutics LLC) administered to patients with CVD or at high risk for CVD on oral lipid-lowering therapy (LLT) who completed one of the phase 3 base studies.Dr Dean Kereiakes (The Ohio State University, Ohio, US) joins us onsite at AHA Conference to discuss the findings from LIBerate-OLE … View more

Prevention & Chronic Conditions
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 1 month ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 6 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Clinical Clues in Cardiovascular Disease
Author(s): Yassir Javaid , Faizel Osman , Renate B Schnabel , et al Added: 2 months ago
This six-part interview series, recorded around ESC 2025, brings together leading experts to share strategies for earlier and more accurate detection of cardiovascular disease. The discussions highlight how atypical or subtle symptoms of stroke and heart failure can delay diagnosis, and why vigilance in routine practice is critical.The series also examines sex-specific differences in cardiac… View more

CV Disease in Special Populations

Electrophysiology & Arrhythmia
ESC 23: OCEAN(a)-DOSE Trial Update
Author(s): Michelle O'Donoghue Added: 2 years ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered… View more

Prevention & Chronic Conditions
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 3 weeks ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic